Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method

Daratumumab is a monoclonal antibody that targets CD38, a transmembrane protein expressed on many cells including RBCs and to a greater extent on myeloma cells. It has been used for treatment of multiple myeloma and autoimmune diseases. Transfusion management of patients on such therapy can be challenging as these drugs cross-react with RBC surface antigens and cause panreactivity. Material and methods: A retrospective study of the 68 patients treated with anti-CD38 from 2018-2023 was carried out.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research